HIND

HIND is the shell of the former ReShape Lifesciences, renamed Vyome Holdings after the August 15, 2025 reverse merger with Vyome Therapeutics. It is a clinical-stage specialty pharma that plainly states it 'do[es] not have any products approved for sale and ha[s] not generated any revenue from product sales from the biotechnology segment.' The only revenue — $320K in FY2025 (+24.4% YoY) — is a legacy net service fee from the Sun Pharma antifungal licensing arrangement in India, and even that is shrinking in scope: one dandruff supply agreement was terminated in December 2024. Against that trickle of revenue sits a $10.3M net loss, a -3,269% operating margin, and a -$87.6M accumulated deficit. Putting a P/S of 50.5x on a company whose 'sales' are a service fee is meaningless; there is no fundamental valuation anchor here, only pipeline option value.

The balance sheet looks superficially repaired — $4.98M cash (up from almost nothing), equity of $3.76M, liabilities/equity of just 0.73x — but this is merger cash, not operating strength. Operating cash flow was -$3.75M in FY2025, so the existing cash is roughly a single year of runway, and burn will rise: management plans FDA discussions on a pivotal trial design for lead asset VT-1953 in Q2 2026, and R&D already doubled YoY (+106% to $588K). With only 7.02M shares outstanding and a $16M market cap, funding that trial almost certainly means a dilutive raise. The share count already fell 37.8% (reverse split around the merger), which is why the -$4.86 diluted EPS looks 'improved.'